JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
https://jbmtct.com.br/seer/index.php/jbmtct
<p>The JBMTCT is an official electronic scientific publication of the Brazilian Society of Bone Marrow Transplantation (SBTMO), created in 2020, edited every three months and in compliance with a defined editorial policy.</p> <p>Publishes letter to the editor, unpublished articles, review articles, short communication, opinion articles, case reports, conduct protocols and research articles in progress / completed with the aim of spreading knowledge and innovative research in medicine fields, bone marrow transplantation, cell therapy and related sciences.</p> <p>Target audience: this journal is aimed to researchers, teachers, professionals and students with an interest in the medicine field (bone marrow transplantation and cell therapy) and related sciences.<br /><br />Periodicity of the jornal:<br />Quarterly</p>Sociedade Brasileira de Transplante de Medula Ósseaen-USJOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY2675-374XCommentary article on AI and EI
https://jbmtct.com.br/seer/index.php/jbmtct/article/view/237
Hans-Jochem Kolb
Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-07-242024-07-245223723710.46765/2675-374X.2024v5n2p237HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR ALL: A report from the 2024 Congress of the Brazilian Bone Marrow Transplantation and Cellular Therapy Society (SBTMO)
https://jbmtct.com.br/seer/index.php/jbmtct/article/view/244
<p>This article analyzes current data, and the main challenges faced in Hematopoietic cell Transplantation (HCT) in Brazil, as presented at the SBTMO 2024 meeting, with the aim of guiding future actions. Topics discussed included the waiting list for HCT transplants, access to beds for adults and pediatric patients, and the need for a more efficient distribution of resources across the country. Among the identified needs were the creation of a program to expand access to transplants through the Brazilian Unified Health System (SUS), the importance of health registries for data-driven decisions, and the development of the <em>"Mais Saúde Amazônia"</em> project to expand transplant centers in the Amazon region. Additionally, the provision of financial incentives for transplant centers, the implementation of mentorship programs to increase access to HCT, and the formation of a cooperative network between SBTMO (Brazilian Society of Bone Marrow Transplantation and Cellular Therapy), ABHH (Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy), ANVISA (Brazilian Health Regulatory Agency), ABRALE (Brazilian Association of Lymphoma and Leukemia), and INCA (Brazilian National Cancer Institute) to improve the integration of HCT services were discussed</p>Fernando Barroso DuarteKarine Sampaio Nunes BarrosoLuiz Guilherme Darrigo JuniroCarmem Maria Sales Bonfim
Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-09-252024-09-255224424410.46765/2675-374X.2024v5n2p244EMERGING ACTIVITY OF CELLULAR IMMUNOTHERAPY FOR TREATMENT OF CANCER IN BRAZIL
https://jbmtct.com.br/seer/index.php/jbmtct/article/view/235
<p>Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved for standard of care treatment of patients with lymphoma and leukemia worldwide. Here we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and Center for International Blood and Marrow Transplant Research (CIBMTR). A total of 38 patients who received CAR T cells between 2020 and 2023. The median age was 47 years (range 4-77). Indications include Non-Hodgkin Lymphoma (NHL; 26 cases; 68%), Acute Lymphoblastic Leukemia (ALL; 9 cases; 24%), and Multiple Myeloma (MM; 3 cases; 8%). 84% (75% - 24 NHL cases and 25% - 8 ALL cases) were commercial. This report demonstrates the initial implementation of CAR T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements. </p>Cinthya Corrêa da SilvaAnderson João SimionePaula Moreira da Silva SabainiAntonio Vaz MacedoHeliz Regina Alves das NevesMonique Ammi Flavia Ferreira da CostaValeria VianaAdriana Mendes de Quadros CavilhaRosana Rocha ConcilioPhillip ScheinbergNelson HamerschlakMarco Aurelio SalvinoAdriana Seber Yana Augusta Sarkis NovisVanderson Geraldo RochaJoaquim Gasparini dos SantosLucia Mariano da Rocha SillaRicardo ChiattoneAndreza Alice Feitosa RibeiroVaneuza Araújo Moreira FunkeLeonardo Javier ArcuriLucila Nassif kerbauyJayr Schmidt FilhoCarmem Maria Sales BonfimSimone Ojima FerreiraMarcelo PasquiniFernando Barroso Duarte
Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY
https://creativecommons.org/licenses/by-nc-sa/4.0
2024-07-242024-07-245223523510.46765/2675-374X.2024v5n2p235